SKSunny H. Kim

Sunny H. Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sunny H. Kim has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Arshad Jamal Ansari

    Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA

    2 shared publications
  • Guoyun Kao

    Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA

    2 shared publications
  • Srinivasarao Singireddi

    Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA

    2 shared publications
  • Yong Zhang

    University of Southern California

    2 shared publications
  • Zeyu Zhang

    Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA

    2 shared publications
  • Benjamin B. Katz

    Department of Chemistry University of California Irvine CA USA

    1 shared publication

Latest Publications

  • Open Access

    Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases

    by Sunny H. Kim, Arshad J. Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B. Katz, Yong Zhang

    Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual‐targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP‐ribosyl cyclase family, and its covalent inhibitor. A model ADP‐ribosyl cyclase‐enabled bispecific conjugate (ARC‐BsC) against human T‐cell CD3 and prostate‐specific membrane antigen (PSMA) is generated through site‐specific conjugation of an anti‐CD3 antibody‐CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small‐molecule ligand. The resulting ARC‐BsC can redirect and activate cytotoxic T cells toward killing PSMA‐expressing tumor cells, eliciting highly potent and selective anti‐cancer immunity in vitro and in vivo. This proof‐of‐concept work demonstrates ARC‐BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.


  • Open Access

    Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases

    by Lei Zhang, Mashael F. Aldossari, Arshad J. Ansari, Guoyun Kao, Sunny H. Kim, Thuc Oanh Hoang, Kaiyu Shen, Zeyu Zhang, Srinivasarao Singireddi, Zekun Li, et al.